Navigation Links
Macular Degeneration Specialists Introduce New Eye Vitamin Called Focus MaculaPro
Date:1/31/2012

GREENBELT, Md., Jan. 31, 2012 /PRNewswire-iReach/ -- Summary: Over 400 retina specialists, the doctors who treat macular degeneration, start a new company called Covalent Medical, LLC to manufacture and distribute a new macular health eye vitamin called Focus MaculaPro.

(Photo: http://photos.prnewswire.com/prnh/20120131/CG43611)

The number of patients suffering from age-related macular degeneration is expected to skyrocket over the coming years.  Age-related macular degeneration (also known as AMD) is already the leading cause of vision loss for people over the age of 55 in the United States.  However, over the next several decades researchers estimate that the number of patients afflicted with macular degeneration will double.

Fortunately, the National Eye Institute (NEI) says that the risk of vision loss in patients with macular degeneration can be reduced dramatically simply by taking specific eye vitamins.   The NEI-sponsored Age-Related Eye Disease Study (AREDS) showed that the rate of severe vision loss can be decreased by as much as 35% by taking a specific combination of Vitamin A, Vitamin C, Vitamin E, Copper, and Zinc.  The levels of these vitamins cannot be achieved through diet alone, so vitamin supplementation is critical.

Unfortunately, many people who should be taking a macula vitamin supplement aren't doing so.   Of the 8 million people whom the NEI estimates would benefit from taking a macular health vitamin, studies have shown that less than half are taking a vitamin consistent with the AREDS study.  Confusion about different formulations and affordability are two of the leading causes of poor compliance.   Improved compliance could prevent approximately 300,000 people from developing the advanced form of the disease over five years.

Now, however, a new company is set to revolutionize the eye vitamin industry and take on this public health issue.  CovalentMedical, LLC, was started in 2011 by a group of over 400 macular degeneration specialists to manufacture and distribute an affordable, high-quality, physician-recommended macular health eye vitamin called Focus MaculaPro (http://www.focusvitamins.com).  The medical doctors who founded the company represent approximately 50% of the retina specialists in private practice in the United States and are dedicated to fighting macular degeneration.   As macular degeneration experts, they collectively treat hundreds of thousands of patients annually and see first-hand the devastation that macular degeneration can cause.   

The physicians behind Focus MaculaPro were frustrated by the lack of good vitamin options for their patients.  Some macular health vitamins have either inadequate levels of the vitamins proven to prevent vision loss or contain ingredients that are not well-researched by the NEI.  Many eye vitamin products cost $30, $40, or $50 or more per month.  Focus Macula Pro, however, will be sold in doctors' offices for only $10-15 per month to promote more widespread eye vitamin usage in the at-risk population.

David Williams, MD, MBA, immediate past-president of the American Society of Retina Specialists states "As macular degeneration specialists, we recognize the critical role that eye vitamins play in ocular health.   Now with Focus MaculaPro our patients and the public have access to a high-quality, research-based, affordable eye vitamin."

While Focus MaculaPro is less expensive than many other brands, it is an extremely high-quality product.  Focus MaculaPro is manufactured in a facility registered by the Food and Drug Administration and laboratory tested to assure quality and safety.   Additionally, Focus MaculaPro is based on the formula used in the AREDS eye vitamin study.   Unlike other products on the market, important vitamins are included in amounts indicated by the AREDS study and untested supplements, like bilberry and selenium, are not utilized.

The doctors of Covalent Medical hope that by working together as a group to produce a high-quality, science-based, affordable macular health vitamin like Focus MaculaPro they can improve compliance, promote eye health, and save the United States healthcare system millions of dollars.

About Covalent Medical

Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is the largest commercial organization of retina specialists in the country.  Covalent Medical is a patient-focused company that produces research-based eye vitamins that are sold directly through eyecare professionals, through their website at http://www.focusvitamins.com, and through retail outlets.  Focus Macula Pro was specifically developed for macular health.

Contact Information:  Rebecca Freitag, Communications Director at Covalent Medical, LLC , can be reached at info@focusvitamins.com or (855) 663-6287.

Media Contact: Rebecca Freitag Covalent Medical, LLC, (855) 663-6287, info@focusvitamins.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Covalent Medical, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UKs National Health System Rejects Drug Therapy for Diabetic Macular Edema
2. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
3. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
4. First Patient Receives FDA-Approved Telescope Implant for End-Stage Macular Degeneration
5. Medicare Establishes Reimbursement for VisionCares Implantable Telescope for Macular Degeneration
6. KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema
7. VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration
8. FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
9. Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
10. FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
11. Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has ... report to their offering. ... The report forecasts the global optical transceiver market ... The report covers the present scenario and the ... calculate the market size, the report considers the revenue generated from ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... , ... "I have gout, and I wanted to treat it naturally," said ... to relieve gout and pain caused by varicose veins. I drank it every morning ... relieved what VA doctors called the worst sinusitis case they'd seen and relieved gas, ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric ... patient safety. Only a few hospitals and facilities have earned this distinction. This ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
Breaking Medicine News(10 mins):